The unsung hero behind accurate cancer diagnoses: why reference standards matter.

When a cancer test result reaches a clinician, it appears as a single answer. But behind that clarity lies a chain of complicated processes, each calibrated, validated, and rigorously quality-controlled. In cancer diagnostics, accuracy isn't optional, and there is absolutely no room for guesswork.

Precision medicine holds an extraordinary promise, treatments tailored to the unique genetic makeup of each patient's tumor. But between that bold promise and a life-changing therapy lies a complex diagnostic workflow. And in that space, even the smallest variation can alter the outcome.

So, how do laboratories ensure their equipment is calibrated, their workflows are consistent, and their results are reproducibly reliable? That's where reference standards make all the difference.

When sensitivity isn't enough

Next-generation sequencing (NGS) and droplet digital PCR (ddPCR) can detect mutations at very high sensitivity. But sensitivity alone doesn't guarantee precision.

How does a lab know if the detected mutation is real?

How does it confirm the assays and workflows are performing as expected?

How does it maintain consistency across instruments, operators, and time?

This is where confidence is either built or lost.

Reference standards provide the essential checkpoints of modern oncology testing. Designed with known mutations that mimic real patient samples, they verify each step of the workflow, from DNA extraction to sequencing accuracy, and data interpretation.

Without them, most advanced platforms risk becoming powerful tools without a safety net.

The gap is clear, and it's not technological, it's the gap between breakthrough technology and dependable answers, between generating data and trusting it.

Why it's more important than ever

As precision medicine advances, cancer treatments are increasingly tailored to the molecular signature of each individual tumor. It is life-saving progress, but only when the diagnosis is accurate.

Inconsistent or unreliable test results could lead to:

• A missed opportunity to receive a life-extending therapy
• Exposure to therapy that may not be effective or cause unnecessary side effects
• Delayed treatment due to repeat testing

Reference standards help prevent these risks by allowing laboratories to verify that assays are performing optimally, and workflows are functioning as they should.

But not all standards are created equal.

Why cell line-derived standards matter

Many reference materials today are synthetically created in a lab with clean, engineered DNA. While useful, they don't fully replicate the complexity of human DNA. That's why our Mimix™ reference standards are derived from human cell lines. These preserve the natural genomic architecture, making them more realistic and more reliable.

This level of fidelity is essential, especially in complex cancer panels where laboratories must accurately detect dozens or even hundreds of mutations simultaneously.

Raising the bar in diagnostic confidence

With the launch of the five Mimix IVD standards, we bring over 14 years of experience into clinical labs that need trustworthy tools more than ever. These standards meet FDA requirements for IVD use, meaning they're made to high standards to help labs monitor variation, catch errors, and keep performance tight from run to run.

It's time to give reference standards the spotlight

They may not grab headlines, but reference standards are the quiet champions of modern diagnostics. They help bring consistency to complexity. They help protect precision medicine from variation.

Precision medicine isn't just about detecting what's there. It's about ensuring every result can guide the right treatment. From innovation to implementation and from complexity to confidence.

Bridging the gap in cancer diagnostics. Challenge accepted.